© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Pazopanib grew out of a crowded field of kinase inhibitors aiming to block the critical blood supply that tumors need to grow. Back in the early 2000s, the search for small molecules that could selectively hamper vascular endothelial growth factor receptors (VEGFRs) picked up steam after basic research tied these pathways to relentless tumor expansion. In 2009, regulatory agencies in the U.S. and Europe approved pazopanib for advanced renal cell carcinoma, recognizing its value for patients with few options. A few years later, its indication expanded to certain soft tissue sarcomas after clinical trials revealed better progression-free survival compared to sugar pill controls. The story of pazopanib mirrors changing cancer treatment attitudes: push hard on targeted therapies, step around chemotherapy’s hard limitations, relentlessly study real patient responses, and accept setbacks as part of the route to progress.
Marketed under the brand name Votrient, pazopanib comes in tablet form. Pink or white film-coated pills line pharmacy shelves with doses marked 200 mg and 400 mg. Each tablet contains the active ingredient along with stabilizers such as microcrystalline cellulose, povidone, and magnesium stearate. Rather than sweeping through every cancer, its niche orbits renal cancer and certain types of sarcomas, especially in adults. Prescription use rides on oncologist judgment, disease stage, prior lines of therapy, and overall patient health. Many patients receive it as a next-step drug after surgery or when the tumor no longer shrinks with standard therapies.
Pazopanib hydrochloride is a white to yellow crystalline powder with poor water solubility. Its molecular formula clocks in at C21H23N7O2S·HCl; molecular weight hits about 473 g/mol. It tends to dissolve better in acids, which matters when considering how stomach acidity impacts absorption — the issue pops up when patients use acid-blocking medicines. The compound stays relatively stable under normal storage conditions, but like most drugs hates exposure to excessive heat, sunlight, or moisture.
Regulators hammered out specific requirements for pazopanib’s purity, identity, and dosage forms. Each production batch gets tested by HPLC for active drug content, related substances, and degradation products. Tablets must contain consistent amounts of the active compound, checked by independent labs and reported in certificates of analysis. Labeling shows all inactive ingredients, storage instructions, recommended dosages, and safety warnings such as a risk of liver toxicity and high blood pressure. Boxes must display batch numbers, expiry dates, and tamper-evident seals to cut down on counterfeiting.
Scaling up synthesis of pazopanib calls for expertise in multi-step organic reactions. Chemists start with a substituted aniline core, ring-closing, chlorination, and sulfonylation steps, among others, before reaching the desired product. Yields and purification matters land squarely in process optimization. Teams use recrystallization, column chromatography, and lyophilization to get clean drug product. Transitioning from bench scale to large-batch commercial production involves close monitoring of impurities. Suppliers must continuously tweak their methods in response to regulatory batch failures and new impurity detection technologies.
Research teams keep tweaking the chemical scaffold to see if analogs or metabolites could improve patient outcomes or dial back toxicity. The main molecule contains groups susceptible to site-directed modification, opening doors for structure-activity relationship studies. Some of pazopanib’s metabolites come from oxidative demethylation and glucuronidation, involving major liver enzymes. Scientists look hard at these changes, not just from a curiosity angle, but to anticipate and manage drug-drug interactions or hepatic toxicity events.
Beyond Votrient, pazopanib appears in the scientific and regulatory literature under names like GW786034 and pazopanib hydrochloride. Sometimes suppliers simply use the chemical descriptor or development codes for tracking in trial registries. This can create confusion for both patients and providers, making consistent color codes, packaging, and prescription guidance important in clinical use. In generics markets, brands may trump up their own minor variations, but active drug content and performance stand regulated by national medicines agencies.
Hospitals, clinics, and pharmacies handle pazopanib under strict safety guidance, given its impact on liver enzymes, heart function, and bleeding risk. Oncology nurses receive training to spot symptoms early: jaundice, shortness of breath, or changes in heart rhythm. MSDS documentation outlines risks for workers, covering skin contact, inhalation, and environmental disposal. Regulatory authorities set out proper documentation for chain-of-custody, so that from warehouse to patient, every step can be traced back if problems emerge. Patients need monthly blood work, especially liver panels, and clear counseling about food interactions or over-the-counter drugs that could interfere.
Doctors turn to pazopanib primarily for metastatic renal cell carcinoma and advanced soft tissue sarcomas after surgery or other therapies lose effect. Its use in these areas recognizes a lack of curative paths and the need for manageable side effects over months or years. Clinical trials continue searching for roles in other solid tumors: ovarian cancer, non-small cell lung cancer, even some rare sarcomas. Off-label use pops up, but so does insurer scrutiny and the need for evidence. The drug shows modest success improving survival times or shrinking tumors, but complete remissions stay rare. Personal experience working with oncology teams highlights a push toward personalized medicine, yet patient access depends on insurance coverage, geography, and hospital protocols.
Current research circles around making pazopanib more tolerable, extending its benefits and identifying patient groups who genuinely respond. Some trials combine it with immune therapies or other kinase inhibitors to spot potential synergies. Researchers dive into genetic markers, hoping to find signs that predict strong response or warn of serious side effects. Studies compare real-world patient outcomes with those found in classic clinical trials, trying to close the gap between theory and practice. Meanwhile, preclinical experiments keep spinning out analogues or next-generation molecules hoping for longer action or fewer adverse reactions.
Safety profiles for pazopanib bring tough trade-offs. Damage to the liver and elevated blood pressure show up more often than with many older drugs. Regular blood tests, blood pressure tracking, and patient-reported symptom monitoring form the front line against serious injury. Animal studies nailed down potential for fetal toxicity, so usage in pregnancy stays strictly controlled. Cross-talk with other medications via cytochrome P450 enzymes exposes more chances for unexpected side effects. From firsthand hospital experience, many patients tolerate mild nausea and fatigue, but significant numbers drop out or switch drugs because of liver test spikes or intractable hypertension.
Interest in pazopanib’s future focuses on combination treatments and fine-tuned dosing. Generic forms will widen access, but questions about real-world performance and risks grow larger as broader patient groups get exposed. Efforts to adapt its chemical structure could lead to versions that limit off-target effects or last longer in the body. Integration with genetic testing might let clinicians pick only those most likely to benefit. Research on ways to protect the liver and heart during long-term treatment holds real value, since current methods still rely on stopping or reducing doses. Over time, demand for non-chemo cancer options will keep pressure on researchers and regulators to build off the lessons learned from pazopanib’s first decade. Cancer care changes fast, but the experience gained from decades of molecular and clinical research lays the groundwork for smarter and safer drugs for years to come.
Cancer often feels like a word shrouded in fear and uncertainty. After years of meeting patients and their families, I’ve seen first-hand how hope gets tied up with every pill and treatment option. Among the newer medicines, pazopanib has managed to create a foothold. People don’t pick up this medication on a whim. Doctors prescribe it with a clear intent: to slow down cancers that spread fast and grow deep roots, especially types that don’t respond well to other treatments.
Pazopanib comes up most often during difficult conversations about advanced renal cell carcinoma, which starts in the kidneys. Many also know it as a go-to for certain soft tissue sarcomas. Doctors don’t talk about it as a miracle cure, but they see it as a lifeline—a drug that can keep cancer from taking over the body too soon. It’s taken as a tablet, and that alone makes life easier for patients who want to spend less time in hospitals. The research community keeps following its progress, and studies have shown that the drug works by blocking certain signals cancer cells need to grow. This signal comes from proteins in the blood that tumors seem to crave.
What struck me most in all the reading I’ve done is that pazopanib targets blood vessel growth. Tumors take nutrients through blood vessels, building their own highway. Pazopanib acts like a roadblock, disrupts these lines, and starves the tumor’s supply. One of the main proteins it blocks is called VEGF, short for vascular endothelial growth factor. Cancer often depends on this signal, and when you block it, the disease slows down. This kind of targeted therapy causes less harm to healthy cells around the tumor, so patients don’t always experience the same side effects as older chemo drugs.
For people with advanced kidney cancer, one study published in the New England Journal of Medicine reported that pazopanib led to months of extra time before the disease got worse, compared to a sugar pill. Families hanging onto small steps forward see that as real progress. Still, it’s important to weigh side effects. Not everyone tolerates it the same way. Some get high blood pressure, changes in hair color, liver trouble, or diarrhea. Honest conversations matter here. Patients and doctors decide together if keeping cancer at bay is worth more than dealing with tough symptoms.
Pazopanib costs a lot, and that limits who can use it. Insurance battles become part of the cancer journey. I once helped a patient spend hours with phone calls and forms to get help paying for this drug. Inequality hits hard—some manage to get it, some don’t, and the difference comes down to resources and support systems. It’s tough to watch, because advances in medicine only mean something when real people can reach them.
Scientists still push to learn more. They test pazopanib in combination with other therapies and for new cancer types. I hope broader use of genetic testing will show who gets the most benefit with the least cost to their health and wallet. Until then, pazopanib stands as both a tool and a symbol—a sign that cancer research moves on, slowly, but with real impact on the lives of those facing some of the hardest days of their lives.
Pazopanib gets prescribed for people facing advanced kidney cancer or soft tissue sarcoma. Looking at real-life stories, the medication doesn’t take it easy on folks. People often worry about what’s coming. So, let’s talk about those common side effects that many run into, not just what a tiny label lists.
Medical trials and everyday clinics both see stomach issues pop up the most. Nausea, belly cramps, and, yes, diarrhea hit a lot of people. These side effects can make it hard to keep weight on or even enjoy a meal. It’s not just a minor annoyance — families often work around mealtimes or figure out which foods sit a little easier. Some struggle with vomiting, which can mess up workdays or social plans. About half of the people on pazopanib fight with diarrhea at some point.
Changes in taste throw another curveball. Coffee or favorite snacks can suddenly taste like metal or nothing at all. Our senses mean a lot for enjoying little things, and this side effect makes life less colorful. Medical research teams report that more than 25% of patients mention not wanting to eat anything thanks to this change.
Liver numbers draw attention during checkups. Doctors ask for regular blood tests to catch the trouble early, since pazopanib can bump liver enzymes beyond a safe range. Anything above the normal number triggers a talk about lowering the dose or stopping the drug.
Fatigue steps in pretty often. People describe a heaviness, like walking through wet concrete, making daily chores feel huge. Studies show nearly 3 in 5 folks taking pazopanib deal with this fatigue. Less energy changes how someone shows up for work, what they can do at home, and how they cope with everything else cancer throws at them.
Blood pressure climbs for a lot of people. Hypertension from pazopanib creeps up without warning, so doctors don’t just hand out this drug—good monitoring follows. Patients can sometimes need new medicines just for blood pressure alone. If it goes unchecked, the risks go beyond annoyance and start getting serious, hitting the heart or kidneys hard.
Hair color shifts surprise people — white or gray hair can show up after a few months. This doesn’t hurt, but it’s often the most visible sign that something major is changing under the skin. It’s a daily reminder of what patients are facing.
Hand-foot syndrome also causes swollen, red, painful skin on hands or feet. This makes walking or even turning a doorknob tough. Solutions sometimes mean switching up shoes, using lots of lotion, or getting help with daily chores. This side effect doesn’t threaten life, but it can sap joy and independence.
Pazopanib has a clear role in fighting serious cancers, and it keeps some cancers under control for longer. But side effects — from stomach trouble to changes in taste, fatigue, and liver strain — take a toll. Oncologists stick to a tight schedule of bloodwork and check-ins for a reason. At home, keeping a diary of symptoms and reaching out to your healthcare team right away can keep those side effects from getting out of hand. Listening to patients about which symptoms bother them the most helps craft a plan that works in the long run. Families, friends, and support groups become a lifeline, sharing tricks and encouragement to make daily life possible despite the storm pazopanib can bring.
Pazopanib shakes up daily life. Folks facing kidney cancer or soft tissue sarcoma often meet this pill after seeing their diagnosis written on cold white paper. It isn’t just another medicine on the shelf—its effect relies on careful habits and know-how that go beyond reading the label. Doctors can spell out guidelines, but in the end, patients live them out. Having gone through medication routines more than once myself, the day-to-day reality rarely matches the textbook description.
A lot of drugs allow wiggle room. Pazopanib does not. People take one tablet a day, swallow it whole—never crushed or chewed—with a glass of water. Nothing fancy there. But here’s where things get real: this medicine wants to be taken on an empty stomach. Unpredictable absorption can mess with how the drug works, and research shows that fat or protein in food can ramp up its presence in the body, leading to higher risk of side effects. So, the advice: wait one hour before eating or two hours after your last meal. As I’ve learned with other fasting medicines, keeping to this routine can feel awkward, especially for folks tied to family meals or busy jobs. Missing a dose once or twice can happen, but sticking to the same time every day makes a huge difference, both in results and peace of mind.
Cancer drugs, especially targeted ones like pazopanib, command respect and attention. Safety isn’t just a matter of avoiding a few foods. Grapefruits and their juice fire up liver enzymes and block the breakdown of the drug—unwelcome in the bloodstream and easy enough to skip for breakfast. The bigger battle may come from symptoms. Nausea, tiredness, and changes in hair color can sneak in, but the more pressing risks hide in numbers—high blood pressure or changes that show up in liver tests. I remember the worry that sets in while waiting for lab results, hoping the next round of pills won’t be postponed. Folks need straightforward access to regular blood tests, frequent blood pressure checks at home, and honest talks with their cancer team. Hormones, reactions with other medications, and complications can pop up, so simple check-ins become the shield that keeps treatment possible.
Practical routines beat complexity every time. Setting a phone alarm, linking pill time with brushing teeth, or leaving the bottle out by the coffee mug all nudge memory along. A support person—a family member, maybe, or a friend—makes it easier, too. In my own experience, having another set of eyes, someone who asks, “Did you take your pill?” makes a difference on the rough days. For those fighting cancer, uncertainty comes by default. Pazopanib’s rules can stack stress, but tools like pill organizers or setting reminders through care apps take the guesswork away.
Taking pazopanib isn’t just about swallowing a pill. Open, early conversations with doctors or pharmacists give people the best shot at handling side effects, tweaking the dose if needed, and keeping treatment on track. In the crunch of dealing with illness, patients often downplay troubles, hoping to be “good patients.” That mindset can get in the way of winning the real fight. Speaking up, sharing worries, and telling the truth about side effects or missed doses gives the medical team a chance to support true progress.
No cancer journey feels simple, and adding new medications makes things even more complex. Doctors prescribe pazopanib mostly to treat kidney cancer and soft tissue sarcoma. This medicine belongs to a group called tyrosine kinase inhibitors. It slows down the growth of cancer by cutting off some of its blood supply. Patients call this pill a lifeline, but every lifeline comes with strings attached—drug interactions stand out as one of the most common, and sometimes most dangerous, strings tied to pazopanib.
Pazopanib does its job in the liver, where it’s broken down by the CYP3A4 enzyme. This same enzyme deals with hundreds of other medications, so there’s plenty of room for collisions. The most common culprits interfering with pazopanib include:
Years sitting across from patients have shown that the complexity of drug interactions isn’t just a theoretical problem. One woman on pazopanib picked up fluconazole at the pharmacy for a yeast infection, not realizing it could spike her liver enzymes. Quick adjustments and extra bloodwork helped her sidestep liver damage, but not everyone gets lucky. Once, a man’s heart rate soared after mixing pazopanib with a common macrolide antibiotic—a fast switch kept him safe. Every experience points to communication as the key. Patients, nurses, oncologists, and pharmacists all need to talk openly.
Preventing medication interactions rarely happens by accident. Patients need to share every pill and supplement—prescription or over-the-counter—with their care team. Cancer treatment brings enough stress; patients deserve clear answers and active monitoring. Drug interaction checkers, clinical pharmacists who focus on oncology, and regular bloodwork all make a difference.
Education also stands out as the best first defense. Medical teams who lay out the risks early help everyone avoid pitfalls later. Patients armed with a printed medication list, including vitamins and supplements, often sidestep dangerous mistakes. Family members should join these conversations too, since they end up managing pillboxes, appointments, and pharmacy runs behind the scenes.
Cancer treatment keeps evolving. Medications like pazopanib offer hope, but they also demand vigilance. Open communication, curious questions, and regular check-ups all help. No one gets through cancer alone—sharing responsibility and information across the team can keep patients safer and give them the best shot at benefit without unnecessary harm. The future of cancer care depends on respecting every detail in a patient’s routine, especially the ones that seem the smallest.
Missing a dose feels like a big deal when you’re dealing with cancer or a rare tumor. Life gets busy, brains get foggy, or maybe that pill slipped your mind after a tough day. I’ve sat at the kitchen table with folks reviewing their med schedules, and it doesn’t take much for a routine to go out the window. But missing a pill isn’t the end of the world. It’s what you do next that counts.
Pazopanib isn’t an over-the-counter aspirin. It targets cancer cells and has a strict window for working in your body. Too much in one day can cause big problems—liver issues, high blood pressure, bleeding. Skipping and then doubling up tempts trouble. Drug levels need that steady rhythm. Oncology teams stress regularity because the science shows patient outcomes improve when the body gets medicine predictably. That lesson comes from long-term data, not a hunch.
If you look at the clock and realize you missed your dose by a few hours, breathe. Swallow the tablet as soon as you remember, but only if there’s enough time—about 12 hours or more—before the next scheduled dose. If the window’s tighter, skip the forgotten dose and just resume regular timing. Most oncologists I know underline this at each appointment: No “catching up” or taking two doses at once. Side effects hit harder when levels spike.
Grapefruit and similar foods interact with Pazopanib. These foods push levels up, making side effects more likely. If you ever miss a dose, avoid the temptation to “wash it down” with something tasty. Water does the trick, nothing fancy.
Don’t keep a missed dose under wraps. My experience with health teams tells me that honesty gets people further in their treatment. Your nurses and pharmacists track patterns, spot developing problems, and give solid advice as things happen — not weeks after the fact. Missed more than one dose in a week? Bring it up, even if you feel embarrassed. Support helps, lectures don’t. Sometimes a care partner or reminder system makes all the difference.
Pill containers seem old-fashioned, but for something like Pazopanib, those little boxes save headaches and heartache. Phone alarms work for the tech-minded. Families I’ve seen even set up group chats to nudge each other at med time. Keeping a record in a notebook helps you spot any slip-ups or side effects.
Missing a dose means looking at what got in the way. If nausea, fatigue, or taste made you hesitate, flag it for your doctor. They tweak schedules or offer support if the side effects slow you down. Life with cancer isn’t neat and organized, but your care team aims to give you every possible advantage. Letting a missed dose pass, then jumping back on track, is the best way to keep fighting.
Pazopanib works best with consistency. Don’t worry about perfection. Focus on routines, honesty with your care team, and practical tools to help you remember. Missing one dose doesn’t cancel your progress. It just calls for a little action, a little learning, and some support for the journey.
| Names | |
| Preferred IUPAC name | 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide |
| Other names |
Votrient GW786034 |
| Pronunciation | /pæˈzəʊpəniːb/ |
| Identifiers | |
| CAS Number | 444731-52-6 |
| Beilstein Reference | 1362686 |
| ChEBI | CHEBI:493111 |
| ChEMBL | CHEMBL1201197 |
| ChemSpider | 221017 |
| DrugBank | DB06592 |
| ECHA InfoCard | 100000125887 |
| EC Number | EC 4.1.1.28 |
| Gmelin Reference | 1269274 |
| KEGG | D09538 |
| MeSH | D000068878 |
| PubChem CID | 10113978 |
| RTECS number | Y3537T56ZM |
| UNII | D0T23JVNW4 |
| UN number | UN3248 |
| Properties | |
| Chemical formula | C21H23N7O2S |
| Molar mass | 437.528 g/mol |
| Appearance | White to yellow or greenish-yellow powder. |
| Odor | Odorless |
| Density | 1.282 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.8 |
| Acidity (pKa) | 2.1 |
| Basicity (pKb) | 8.9 |
| Magnetic susceptibility (χ) | -7.1e-6 |
| Dipole moment | 4.55 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -713.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6311.3 kJ/mol |
| Pharmacology | |
| ATC code | L01XE11 |
| Hazards | |
| Main hazards | May cause liver toxicity, hypertension, cardiac dysfunction, hemorrhagic events, and gastrointestinal perforation. |
| GHS labelling | GHS05, GHS07, GHS08 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Pazopanib is a hazardous drug; avoid exposure. Handle with appropriate protective equipment. Avoid inhalation, ingestion, or skin contact. Use in a well-ventilated area. Wash hands thoroughly after handling. |
| NFPA 704 (fire diamond) | 1-2-0-ν |
| Flash point | 113.8 °C |
| Lethal dose or concentration | Rat oral LD50 is >1000 mg/kg |
| LD50 (median dose) | > 1,000 mg/kg (rat, oral) |
| NIOSH | DB06589 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 800 mg once daily |
| Related compounds | |
| Related compounds |
Axitinib Sunitinib Sorafenib Regorafenib Vandetanib Cabozantinib Lenvatinib Cediranib Imatinib |
